These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 21792211

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of liquid chromatography/tandem mass spectrometric molecular fingerprinting for the rapid structural identification of pharmaceutical impurities.
    Li M, Wang X, Chen B, Lin M, Buevich AV, Chan TM, Rustum AM.
    Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3533-42. PubMed ID: 19844969
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n).
    Thomas S, Paul SK, Shandilya S, Agarwal A, Saxena N, Awasthi AK, Matta Hb, Vir D, Mathela CS.
    Analyst; 2012 Aug 07; 137(15):3571-82. PubMed ID: 22733388
    [Abstract] [Full Text] [Related]

  • 7. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
    Freed AL, Kale U, Ando H, Rossi DT, Kingsmill CA.
    J Pharm Biomed Anal; 2004 Jun 29; 35(4):727-38. PubMed ID: 15193717
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
    Háda V, Dubrovay Z, Lakó-Futó A, Galambos J, Gulyás Z, Aranyi A, Szántay C.
    J Pharm Biomed Anal; 2013 Oct 29; 84():309-22. PubMed ID: 23177164
    [Abstract] [Full Text] [Related]

  • 12. Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometry.
    Schneider A, Wessjohann LA.
    J Pharm Biomed Anal; 2010 Nov 02; 53(3):767-72. PubMed ID: 20570457
    [Abstract] [Full Text] [Related]

  • 13. Structural identification and characterization of impurities in ceftizoxime sodium.
    Bharathi Ch, Prasad ChS, Bharathi DV, Shankar R, Rao VJ, Dandala R, Naidu A.
    J Pharm Biomed Anal; 2007 Jan 17; 43(2):733-40. PubMed ID: 16950586
    [Abstract] [Full Text] [Related]

  • 14. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus.
    Boernsen KO, Egge-Jacobsen W, Inverardi B, Strom T, Streit F, Schiebel HM, Benet LZ, Christians U.
    J Mass Spectrom; 2007 Jun 17; 42(6):793-802. PubMed ID: 17511017
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Identification of gentamicin impurities by liquid chromatography tandem mass spectrometry.
    Grahek R, Zupancic-Kralj L.
    J Pharm Biomed Anal; 2009 Dec 05; 50(5):1037-43. PubMed ID: 19577403
    [Abstract] [Full Text] [Related]

  • 20. LC-MS characterization of trace impurities contained in calcium folinate.
    Francese G, Corana F, Meneghetti O, Marazza F.
    J Pharm Biomed Anal; 2005 Sep 15; 39(3-4):757-63. PubMed ID: 15927438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.